An evaluation of the in vitro activity of piperacillin/tazobactam

References

• Roy, C, Fox, A, Scgura, C, et al. Plasmid determined beta-lactamases identified in a group of 204 ampicillin-resistant Enterobacteriaceae. J Antimicrob Chemother 1983; 12: 507–510
   PubMed Web of Science ®Google Scholar
• Aymes SGB. Plasmid-mediated beta-lactamases: relative clinical importance. Beta-lactamases: current perspectives, DM Livermore. Theracom, Winchester 1988; 31–48, In
   Google Scholar
• Sanders CC, Sanders WE. Beta-lactam resistance in Gram negative bacteria: global trends and clinical impact. Clin Infect Dis 1992; 15: 824–839
   PubMed Web of Science ®Google Scholar
• Knothe, H, Shah, P, Krcmery, V, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315–317
   PubMed Web of Science ®Google Scholar
• Sanders, CC, Iaconis, JP, Bodey, GP, et al. Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother 1988; 32: 1365–1369
   PubMed Web of Science ®Google Scholar
• Thomson, KS, Weber, DA, Sanders, CC, et al. Beta lactamase production in members of the family Enterobacteriacae and resistance to beta-lactam-enzyme inhibitor combinations. Antimicrob Agents Chemother 1990; 34: 622–627
   PubMed Web of Science ®Google Scholar
• Wiedemann B. Genetic and biochemical basis of resistance of Enterobacteriaceae to beta-lactam antibiotics. J Antimicrob Chemother 1986; 18(Suppl B)31–38
   PubMed Web of Science ®Google Scholar
• Sanders WE, Jr, Sanders CC. Inducible beta-lactamases: clinical and epidemiological implications for use of newer cephalosporins. Rev Infect Dis 1988; 10: 830–838
   PubMedGoogle Scholar
• Gutman, L, Kitzis, M-D, Yamabe, S, et al. Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harbouring known beta-lactamases. Antimicrob Agents Chemother 1986; 29: 955–957
   PubMed Web of Science ®Google Scholar
• Eliopoulos, GM, Klimm, K, Ferraro, MJ, et al. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis 1989; 12: 481–488
   PubMed Web of Science ®Google Scholar
• Fass RJ, Prior RB. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother 1989; 33: 1268–1274
   PubMed Web of Science ®Google Scholar
• Appelbaum, PC, Jacobs, MR, Spangler, SK, et al. Comparative activity of beta-lactamase inhibitor YTR 830, clavulanate and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes. Antimicrob Agents Chemother 1986; 30: 789–791
   PubMed Web of Science ®Google Scholar
• Facklam RR, Collins MD. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 1989; 27: 731–743
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically M7-A3. NCCLS, Villanova, PA, 1993
   Google Scholar
• National Committee for Clinical Laboratory Standards: Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria M11-A3. NCCLS, Villanova, PA, 1983
   Google Scholar
• Turnidge, J, Lawson, P, Munro, R, et al. A national survey of antibiotic resistance in Staphylococcus aureus in Australian hospitals. Med J Aust 1989; 150: 65–72
   PubMed Web of Science ®Google Scholar
• Jorgensen JH, McElmeel ML, Maher LA. Quantitative antimicrobial susceptibility testing of Haemophilus influenzae and Streptococcus pneumoniae using the E test. J Clin Microbiol 1991; 29: 109–114
   PubMed Web of Science ®Google Scholar
• Seetulsingh P, Hall LMC, Livermore DM. Activity of clavulanate combinations against TEM-1 beta-lactamase producing Escherichia coli isolates obtained in 1982 and 1989. J Antimicrob Chemother 1991; 27: 749–759
   PubMed Web of Science ®Google Scholar
• Moosedeen F, Keeble J, Williams JD. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors. Rev Infect Dis 1986; 8(Suppl)S562–S568
   PubMedGoogle Scholar
• Klare, I, Rodloff, AC, Wagner, J, et al. Overproduction of a penicillin-binding protein is the only mechanism of penicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1992; 36: 783–787
   PubMed Web of Science ®Google Scholar
• Turnidge J. Foreword: Resistance in Intensive Care Units 1990. Merck Sharp and Dohme. 1992, Monograph published by
   Google Scholar
• Wu PJ, Shannon K, Phillips I. Effect of hyper production of TEM-1 beta-lactamase on in vitro susceptibility of E. coli to beta lactam antibiotics. Antimicrob Agents Chemother 1994; 38: 494–498
   PubMed Web of Science ®Google Scholar
• Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Micro Rev 1995; 8: 557–584
   PubMed Web of Science ®Google Scholar
• Rawlinson W, Sorrell TC, Munro R. Infection in neutropaenic patients. Aust NZ J Med 1988; 18: 815–817
   PubMedGoogle Scholar
• Brismar, B, Malmborg, AS, Tunevall, G, et al. Piperacillin-tazobactam versus imipenem for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992; 36: 2766–2777
   PubMed Web of Science ®Google Scholar
• Mouton, Y, Leroy, O, Beuscart, C, et al, Study Group. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1993; 31(Suppl A)87–95
   PubMed Web of Science ®Google Scholar
• Marie, JP, Vekhoff, A, Cony-Makhoul, P, et al. Randomised trial of piperacillin/tazobactam plus amikacin versus ceftazidime plus amikacin in 222 febrile neutropenic patients. ICAAC 1993, poster 647
   Google Scholar
• Kuye, O, Teal, J, De Vries, VG, et al. Safety profile of piperacillin/tazobactam in phase I and phase III clinical studies. J Antimicrob Chemother 1993; 31(Suppl A)113–124
   PubMed Web of Science ®Google Scholar
• Livermore DM. Determinants of the activity of beta-lactamase inhibitor combinations. J Antimicrob Chemother 1993; 31(Suppl A)9–21
   PubMed Web of Science ®Google Scholar